NCT05275426View on ClinicalTrials.gov

A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

August 11, 2025

Study Completion Date

August 11, 2025

Conditions
Ewing SarcomaEwing-Like Sarcoma
Interventions
DRUG

LY2880070

Patients will receive treatment in 21-day cycles with LY2880070 50 mg twice daily orally on days 2-6, 9-13, and 16-20

DRUG

Gemcitabine

Participants will receive treatment in 21-day cycles with gemcitabine 100 mg/m2 intravenously on days 1, 8 and optionally on day 15

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER